@article{3003200,
    title = "The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions",
    author = "Fragoulis, G.E. and Brock, J. and Basu, N. and McInnes, I.B. and Siebert, S.",
    journal = "Allergy: European Journal of Allergy and Clinical Immunology",
    year = "2021",
    volume = "148",
    number = "4",
    pages = "941-952",
    publisher = "ELSEVIER SCIENCE INC 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA",
    doi = "10.1016/j.jaci.2021.08.010",
    keywords = "baricitinib;  filgotinib;  Janus kinase inhibitor;  peficitinib;  tofacitinib;  tumor necrosis factor inhibitor;  upadacitinib;  Janus kinase inhibitor, Article;  cardiovascular disease;  drug approval;  drug efficacy;  drug safety;  herpes zoster;  human;  immunopathology;  infection;  infection risk;  inflammatory bowel disease;  malignant neoplasm;  nomenclature;  pathophysiology;  phase 3 clinical trial (topic);  psoriasis;  psoriatic arthritis;  randomized controlled trial (topic);  rheumatoid arthritis;  spondylarthritis;  venous thromboembolism;  animal;  ankylosing spondylitis;  inflammatory bowel disease;  psoriasis;  rheumatoid arthritis, Animals;  Arthritis, Rheumatoid;  Humans;  Inflammatory Bowel Diseases;  Janus Kinase Inhibitors;  Psoriasis;  Spondylitis, Ankylosing",
    abstract = "JAK inhibitors (JAKIs) are a new class of targeted therapy that have entered clinical practice for the treatment of immune-mediated rheumatic conditions. JAKIs can block the signaling activity of a variety of proinflammatory cytokines and therefore have the potential to mediate therapeutic benefits across a wide range of immune-mediated conditions. Several JAKIs are licensed, and many more are undergoing clinical trials. Here we provide a narrative review of the current and upcoming JAKIs for adult immune-mediated rheumatic and related conditions, with a specific focus on efficacy in rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, psoriasis, and inflammatory bowel disease. The overall safety profile of JAKIs appears largely comparable to that of existing biologic cytokine-targeting agents, particularly, TNF inhibitors, apart from risk of herpes zoster, which is increased for JAKIs. Importantly however, unresolved safety concerns remain, particularly relating to increased venous thromboembolism. © 2021 American Academy of Allergy, Asthma & Immunology"
}